What Is Fenbendazole?

How a Common Veterinary Drug Became Part of My Cancer Recovery Story

When I began my battle with stage 4 cancer, I prayed every day for God and the universe to show me a path to healing. Over time, that path revealed itself through faith, perseverance, medical care, and a combination of traditional and alternative treatments. One of those treatments—Fenbendazole—has become an essential part of my personal protocol.

WHAT IS Fenbendazole?

Fenbendazole is a veterinary antiparasitic medication—commonly used to deworm dogs and livestock. It works by blocking a protein called tubulin, preventing parasites from absorbing nutrients. Scientists later discovered that this same mechanism could affect how cancer cells divide and survive 【1】.

Why I Considered Fenbendazole

I learned about Fenbendazole through research, other patients, and my wife Sarah, who played a major role in finding integrative approaches that could complement my medical treatments. At first, I was cautious. It wasn’t FDA-approved for human use against cancer, and there was limited clinical data. But I kept reading, praying, and consulting trusted sources.

I discovered several lab and animal studies showing promising results: Fenbendazole appeared to slow tumor growth and induce cell death in certain cancer models 【2】【3】. While I understood these weren’t human trials, the science intrigued me enough to explore it further—carefully, and under supervision.

How Fenbendazole May Affect Cancer Cells

Cancer cells are known for being energy-hungry. They thrive on sugar (glucose) to fuel their rapid growth through a process called aerobic glycolysis, also known as the Warburg effect. Instead of using oxygen efficiently, cancer cells consume glucose at extremely high levels—essentially hoarding energy to multiply uncontrollably.

Early studies suggest that Fenbendazole may interrupt this process. By binding to microtubules (the cell’s internal scaffolding), Fenbendazole can disrupt how nutrients and energy are transported inside cancer cells. When this transport system fails, glucose metabolism slows down, depriving the cancer of its primary energy source 【4】【5】.

This disruption doesn’t just weaken the cell—it can trigger apoptosis, or programmed cell death. In healthy tissue, apoptosis is a natural process that removes old or damaged cells. Cancer cells, however, often find ways to “turn off” that self-destruct mechanism. Fenbendazole appears to help reactivate it, allowing the body to identify and remove malfunctioning cancer cells 【2】【6】.

While most of this evidence comes from lab and animal studies, it offers a promising explanation for why some patients, including myself, may experience measurable improvements when using Fenbendazole as part of an integrative cancer treatment plan.

Integrating Fenbendazole Into My Treatment Plan

I take Fenbendazole as part of a broader, integrative approach that includes Keytruda immunotherapy, high-dose IV vitamin C, Ivermectin, Methylene Blue, and a modified Carnivore diet. This combination—guided by both faith and evidence—has produced results that even my doctors described as “remarkable.”

My most recent CT scan showed my cancer shrinking by up to 50%.
It’s hard to describe what it feels like to see that report after years of fighting. Relief, gratitude, and awe all at once. I don’t claim Fenbendazole alone caused that improvement, but I do believe it has played a meaningful role alongside my other treatments, nutrition, and prayer.

What the Science Says So Far

  • Research evidence: Early studies show Fenbendazole may disrupt glucose metabolism in cancer cells and promote programmed cell death (apoptosis) 【2】【3】【4】【6】.
  • Human data: Currently, there are no large-scale clinical trials confirming its safety or effectiveness for human cancer treatment 【5】【7】.
  • Safety concerns: Overuse or self-administration without guidance can cause liver toxicity and other side effects 【7】【8】.

Faith and Caution Hand in Hand

I share my story not as medical advice, but as a testimony to faith, persistence, and open-minded healing. Fenbendazole is still considered experimental, and anyone considering it should consult their oncologist and proceed carefully. For me, it has become one piece of a much larger healing journey—one that combines science, spirituality, and relentless hope.

God’s hand has been evident in my progress. Each day I wake up with gratitude, renewed strength, and a reminder that miracles often come through both medicine and faith.

— Wayne Schlicht
Stage 4 Lung Cancer Survivor and Founder of Wayne’s Cancer Journey

Fund Wayne’s Treatment

Sources

  1. NCBI. “Fenbendazole: A Veterinary Anthelmintic Drug.” https://pmc.ncbi.nlm.nih.gov/articles/PMC3580766/
  2. Cho, J. et al. Frontiers in Oncology (2022). “Anticancer Effects of Fenbendazole in Chemoresistant Colorectal Cancer Cells.” https://pmc.ncbi.nlm.nih.gov/articles/PMC9437363/
  3. Kim, E. J. et al. BMC Cancer (2024). “Fenbendazole-Loaded Nanoparticles Suppress Ovarian Cancer in Mouse Models.” https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-13361-9
  4. Zhao, Y. et al. Frontiers in Pharmacology (2023). “Microtubule Disruption and Glucose Metabolism Alteration in Fenbendazole-Treated Cancer Cells.” https://www.frontiersin.org/articles/10.3389/fphar.2023.1172650/full
  5. Anticancer Fund. “Separating Fact from Fiction in Repurposed Drugs for Cancer Treatment.” https://www.anticancerfund.org/en/blog/separating-fact-fiction-repurposed-drugs-cancer-treatment
  6. Singh, K. et al. Molecular Cancer Therapeutics (2021). “Microtubule Destabilization and Apoptosis Induced by Benzimidazole Derivatives.” https://mct.aacrjournals.org/content/20/5/875
  7. Healthline. “Fenbendazole for Cancer: What the Research Says.” https://www.healthline.com/health/pancreatic-cancer/fenbendazole-for-pancreatic-cancer
  8. CancerChoices.org. “Safety of Mebendazole and Fenbendazole.” https://cancerchoices.org/therapy/mebendazole-or-fenbendazole/safety/
  9. Frontiers in Oncology. “Social Media Misinformation on Fenbendazole and Cancer.” https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.942045/full